使用重组霍乱毒素B亚基 (CTB)与恶性疟原虫抗原表位融合蛋白 (AWTE)免疫恒河猴 ,研究其免疫应答并观察对食蟹疟原虫攻击的保护作用。结果表明 :在 0 ,1 4 ,2 8天分别通过鼻腔和肌肉注射免疫恒河猴 ,第 3次免疫后2周 ,抗CTB抗体平均滴度可达 1∶5 1 2 (鼻腔免疫 )和 1∶1 0 0 0 0 (肌肉免疫 ) ;肌肉免疫后抗疟原虫抗体滴度也显著高于鼻腔免疫组。用 1 2 5× 1 0 8个食蟹疟子孢子攻击 ,对照组 5只恒河猴在攻击后 1 0～ 1 4d全部感染 ,其中 1只在攻击后 2 1d死亡 ,另 4只重度感染 ,感染持续 30d以上。鼻腔免疫组的 5只动物均在攻击 2 0d后出现原虫 ,其中 3只轻度感染 ,感染持续 4d后即恢复 ,其余 2只感染持续 36d以上。肌肉注射组 3只未受感染 ,其余 2只在攻击后 1 9d后轻度感染 ,感染 4d后即完全恢复。以上结果表明 ,使用霍乱毒素B亚基为载体蛋白构建的重组疟疾疫苗具有良好的免疫原性 ,对食蟹疟攻击具有良好的交叉免疫保护作用 Rhesus monkeys were immunized with recombinant cholera toxin B subunit (CTB) and Plasmodium falciparum antigen epitope fusion protein (AWTE) to investigate their immune response and to observe the protective effect against challenge with P. meliloti. The results showed that: Rhesus monkeys were immunized by nasal and intramuscular injection on days 0, 14 and 28, respectively. Two weeks after the third immunization, the average titers of anti-CTB antibodies reached 1:51 2 (nasal immunity) and 1 : 1 0 0 0 0 (Muscle Immunity); Anti-Plasmodium Antibody titers after muscle immunization were also significantly higher than those of the nasal immunization group. One hundred and twenty-five macaques were challenged with 1251 × 108 macaques. Five control rhesus monkeys were all infected 10 ~ 14 days after challenge, of which 1 died after 21 days and the other 4 were severe infections. Infection lasts more than 30d. In the nasal immunity group, all the 5 animals showed protozoa after 20 days of challenge. Three of them were mildly infected. The infection was resumed after 4 days and the remaining two were infected for more than 36 days. Three mice in the intramuscular injection group were uninfected, while the remaining two mice were mildly infected after 19 days of challenge and recovered completely after 4 days of infection. The above results indicate that the recombinant malaria vaccine constructed by using the cholera toxin B subunit as a carrier protein has good immunogenicity and good cross-immune protection against malaria attacks